亏损降幅60%！华大智造2025年业绩预告

Core Viewpoint - The company, BGI Genomics (stock code: 688114.SH), has released its earnings forecast for 2025, indicating a significant reduction in losses compared to the previous year, driven by operational improvements and favorable currency exchange impacts [2][4]. Financial Performance - The company expects a net profit attributable to shareholders of between -221 million to -273 million yuan for 2025, a notable improvement from a loss of 601 million yuan in the previous year, representing a year-on-year reduction of approximately 54.56% to 63.22% [4]. - After excluding non-recurring gains and losses, the anticipated net profit is projected to be between -322 million to -397 million yuan, compared to a loss of 653 million yuan last year, indicating a year-on-year improvement of about 39.18% to 50.67% [4]. Reasons for Performance Changes - The company has implemented measures focused on "quality improvement, efficiency enhancement, and return on investment," leading to a decrease in overall costs compared to the previous year [5]. - Currency exchange gains from holding foreign currency monetary items have increased due to fluctuations in the US dollar and euro [5]. - The company has reversed tax provisions related to previous years' uncertain tax disputes, resulting in a reduction in income tax expenses [5]. Company Overview - BGI Genomics is a domestic manufacturer focused on core tools and high-end equipment in life sciences, primarily engaged in gene sequencing and related laboratory automation equipment [6]. - The company emphasizes independent research and development, providing foundational technical equipment and systematic solutions for research institutions, clinical testing laboratories, and industrial clients [6]. Business Segments Gene Sequencing Business - The gene sequencing business is the core segment, continuously upgrading products and reagents to enhance sequencing efficiency, coverage, and application adaptability [7]. - In 2024, the company plans to launch the next-generation sequencing reagent StandardMPS 2.0, along with upgrades to several core sequencing platforms, enhancing their applicability across various research and clinical needs [9]. Laboratory Automation Business - The company is advancing towards systematic and intelligent upgrades in laboratory automation, focusing on key processes such as sample handling, experimental execution, and data analysis [10]. - New products like αLabStudio, αLabRobot, and αCube are being introduced to improve sample management efficiency and experimental stability [12]. New Business Segment - The new business segment focuses on multi-omics tools, ultrasound imaging, and intelligent robotics, aiming to meet cutting-edge research and clinical transformation needs [13][15]. - The company is expanding its capabilities in cell omics, spatiotemporal omics, and proteomics, enhancing high-throughput data collection and analysis [15][16].